Ranbaxy Laboratories Ltd. said its wholly-owned subsidiary Ranbaxy Pharmaceuticals Inc. had launched the authorized generic cevimeline hydrochloride 30 mg capsules in the US market, under an agreement with Daiichi Sankyo, Inc.
Cevimeline hydrochloride is indicated for the treatment of symptoms of dry mouth associated with Sjogren's syndrome, an autoimmune disorder affecting the moisture-producing glands, and is presently distributed by Daiichi Sankyo under the brand name Evoxac.
As per IMS - MAT June 2012, Evoxac generated total annualized sales of $62.4 million in the US
Commenting on the launch, Chairman of Ranbaxy Tsutomu Une said, "We refer to the strategy of optimizing the diverse assets of both companies as our Hybrid Business Model, that will allow both organizations to effectively seize opportunities across the full pharmaceutical value chain and product life-cycle, by leveraging the R&D and manufacturing of both Daiichi Sankyo and Ranbaxy. As such, we will continue to reinforce our respective business platform over the longer term through this hybrid strategy."
At the BSE, Ranbaxy Laboratories shares are being traded at Rs.536.35, up 1.57 percent from the previous close.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.